Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Impact Factor 13.965
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation Research

  • My alerts
  • Sign In
  • Join

  • Impact Factor 13.965
  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Molecular Medicine

C-Terminal Truncation of Cardiac Troponin I Causes Divergent Effects on ATPase and Force

Implications for the Pathophysiology of Myocardial Stunning

D. Brian Foster, Teruo Noguchi, Peter VanBuren, Anne M. Murphy, Jennifer E. Van Eyk
Download PDF
https://doi.org/10.1161/01.RES.0000099889.35340.6F
Circulation Research. 2003;93:917-924
Originally published November 13, 2003
D. Brian Foster
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teruo Noguchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter VanBuren
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne M. Murphy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer E. Van Eyk
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics

Jump to

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters
Loading

Abstract

Myocardial stunning is a form of reversible myocardial ischemia/reperfusion injury associated with systolic and diastolic contractile dysfunction. In the isolated rat heart model, myocardial stunning is characterized by specific C-terminal proteolysis of the myofilament protein, troponin I (cTnI) that yields cTnI1-193. To determine the effect of this particular C-terminal truncation of cTnI, without the confounding factor of other stunning-induced protein modifications, a series of solution biochemical assays has been undertaken using the human homologue of mouse/rat cTnI1-193, cTnI1-192. Affinity chromatography and actin sedimentation experiments detected little, or no, difference between the binding of cTnI (cTnI1-209) and cTnI1-192 to actin-tropomyosin, troponin T, or troponin C. Both cTnI and cTnI1-192 inhibit the actin-tropomyosin–activated ATPase activity of myosin subfragment 1 (S1), and this inhibition is released by troponin C in the presence of Ca2+. However, cTnI1-192, when reconstituted as part of the troponin complex (cTn1-192), caused a 54±11% increase in the maximum Ca2+-activated actin-tropomyosin-S1 ATPase activity, compared with troponin reconstituted with cTnI (cTn). Furthermore, cTn1-192 increased Ca2+ sensitivity of both the actin-tropomyosin-activated S1 ATPase activity and the Ca2+-dependent sliding velocity of reconstituted thin filaments, in an in vitro motility assay, compared with cTn. In an in vitro force assay, the actin-tropomyosin filaments bearing cTn1-192 developed only 76±4% (P<0.001) of the force obtained with filaments composed of reconstituted cTn. We suggest that cTnI proteolysis may contribute to the pathophysiology of myocardial stunning by altering the Ca2+-sensing and chemomechanical properties of the myofilaments.

  • troponin
  • myocardial stunning
  • force-ATPase relation
  • heart failure

Myocardial stunning occurs when transient bouts of ischemia, although not lethal to myocytes, nevertheless impair contractility within the afflicted area of the myocardium (see reviews1,2). In the isolated rat heart model of stunning, ischemia/reperfusion (I/R) reduces myocardial contractility, but the deficit is due to neither poor myocyte excitability nor aberrant Ca2+ handling, which suggests that the lesion of stunning resides within the myofilament.3,4 One myofilament protein, cardiac troponin I (cTnI), undergoes specific and selective proteolysis in response to a mild I/R injury of 15- or 20-minute ischemia followed by reperfusion.5,6 Importantly, cTnI proteolysis correlates with decreased force development in trabeculae or skinned muscle fibers obtained from the stunned myocardium.5,6 Antibody-epitope analysis and mass spectrometry identified cTnI1-193 (equivalent to human cTnI1-192) as the primary proteolytic fragment observed in the stunned myocardium of the rat heart.7 Murphy et al8 constructed a transgenic mouse model in which cTnI1-193 is expressed specifically in the heart. The dilated hearts of the transgenic mice maintain their sarcomeric structure but display both systolic and diastolic dysfunction. Moreover, isolated trabeculae from the transgenic mice that express cTnI1-193 develop diminished maximal Ca2+-activated force compared with trabeculae obtained from control mice, even though truncated TnI constitutes less than 20% of the total TnI in the myofilaments.9 Interestingly, other reports suggest that proteolysis of cTnI (yielding cTnI1-193) is not triggered by myocardial stunning per se but may be attributed to dilatation of the heart caused by elevated preload during the stunning procedure.10 Elevated preload, or increased left ventricular end-diastolic pressure, in itself, is important in the pathogenesis of congestive heart failure. Importantly, cTnI proteolysis is observed in myocardium of patients undergoing coronary artery bypass graft surgery8,11 and heart failure12 and therefore may play a role in human heart disease. Although debate about the precise role of cTnI proteolysis during stunning and heart disease is ongoing, clearly further characterization of cTnI1-193 is warranted to determine the exact molecular consequence of this proteolysis.

TnI is one of the subunits of troponin (Tn), a trimeric regulatory protein complex located on actin-tropomyosin filaments. Tn, together with tropomyosin (Tm), regulates cardiac muscle contraction in response to Ca2+ (see reviews13,14). TnI makes extensive contacts with the other subunits of the Tn trimer, troponin C (TnC) and troponin T (TnT), as well as actin-Tm. In relaxed muscle at low intracellular Ca2+ concentration, by virtue of its interaction with actin, TnI constrains Tm-Tn in a position on the actin filament that prevents myosin binding and subsequent crossbridge cycling. Upon muscle stimulation, elevated intracellular Ca2+ triggers muscle contraction by binding reversibly to TnC. Ca2+ binding causes a region of TnI to switch from its binding site on actin to a site on TnC. This conformational change removes the positional constraint of Tn-Tm on actin and permits the interaction of myosin with actin and the subsequent hydrolysis of ATP (actin-activated myosin ATPase activity) that provides energy for force production.

To determine the functional effect of the specific proteolysis of cTnI, and its possible contribution to the phenotype of myocardial stunning, biochemical analysis of the recombinant cTnI1-192, the human homologue of mouse/rat cTnI1-193, was undertaken. The results reveal that cTnI truncation causes reduced isometric force in a modified in vitro motility assay, despite causing an increase in the steady-state actin-Tm-Tn-S1 ATPase activity.

Materials and Methods

Proteins and Peptides

cTnI, its C-terminal mutant (cTnI1-192), and/or two synthetic peptides used in this study are numbered with respect to the primary amino acid sequence of human cTnI. cTnI193-209 corresponds to the sequence of human cTnI equivalent to the portion cleaved in the stunned rat heart. A longer synthetic peptide, cTnI188-209, was also synthesized to allow detection of any binding site overlapping residue 193 that might be lost or weakened in the shorter peptide. The peptides were prepared using standard F-moc synthesis. Human recombinant cTnI, cTnI1-192, and cTnT were purified by ion exchange chromatography. Human recombinant cardiac TnC (cTnC) was supplied by Spectral Diagnostics (Toronto, Ontario, Canada). Purification of rabbit skeletal actin, rabbit back and/or chicken pectoral skeletal muscle myosin, bovine cardiac and rabbit skeletal αα-tropomyosin (Tm) is described in the online data supplement. Refolding of human recombinant cardiac troponin (cTn) from its constituent subunits was conducted as described previously.17,18 Animals were used in compliance with the Animals for Research Act (Province of Ontario), the guidelines of the Canadian Council on Animal Care, and the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication No. 85-23, revised 1985).

Affinity Chromatography

Human recombinant cTnC (2 mg/mL) and cTnT (2 mg/mL) were coupled to CNBr-activated Sepharose 4B (Pharmacia). A mixture of cTnI and cTnI1-192 (50 μg each), or each synthetic peptide individually, was applied to cTnC or cTnT affinity columns in equilibration buffer (10 mmol/L imidazole pH 7.5, 20 mmol/L NaCl, 1 mmol/L EGTA, 1 mmol/L DTT, and 0.01% NaN3). The peptides and proteins were eluted using a gradient (linear or step) of increasing NaCl, followed by a urea gradient up to 8 mol/L urea. Visualization of cTnI or cTnI1-192 was carried out by Coomassie Blue–stained 12% SDS-polyacrylamide gels, while the peptides cTnI193-209 and cTnI189-209 were analyzed by reverse-phase HPLC (Varian) as previously reported.21 Details are found in the online data supplement.

Actin-Binding Studies

F-actin (2 nmol) was mixed with 0.4 nmol of Tm and increasing quantities of cTnI or cTnI1-192, in 200 μL of binding buffer. Protein mixtures were allowed to equilibrate for 30 minutes before centrifugation at 107 000g in a Beckman TL-100 ultracentrifuge at room temperature. This pelleted 90% to 99% of the F-actin. Pellets were rinsed, once gently, with binding buffer, and dissolved in 100 mL of reducing SDS sample buffer (New England Biolabs). Pellets and supernatants were analyzed by 12% SDS-PAGE. Gels were stained with Coomassie Blue. Densitometric analysis was conducted using Scanplot v5.06 (Cunningham Software).

Determination of ATPase Activity

Assays were conducted in a 96-well ELISA plate (200 μL of reaction volume). Inorganic phosphate was determined colorimetrically as described by Chifflet et al.19 All assays were performed in triplicate; means were plotted as standard deviations. Details are found in the online data supplement.

In Vitro Motility Assay

Thin filaments were reconstituted as previously described,20 labeled with rhodamine-phalloidin at 1:1 actin/phalloidin ratio, and stored overnight at 4°C before use in the in vitro motility assay. The in vitro motility assay has been previously described in detail.20–22 Statistical comparisons were performed, from the parameters of the fit, by use of the t test. All values are expressed as mean±SE. For further detail, see the online data supplement.

A modified in vitro motility assay was used to measure the effects of cTnI truncation on an index of isometric force. VanBuren et al23 and others24 have characterized this technique, in detail, with consistent results. Briefly, α-actinin was attached to a myosin S1-decorated nitrocellulose coverslip surface (15 to 100 μg/mL) followed by a bovine serum albumin wash (0.5 mg/mL). Reconstituted thin filaments (10 to 20 nmol/L) were then added to the motility surface. Motility was initiated with the addition of low-salt motility buffer (see online data supplement). Relative isometric force was defined as the minimum amount of α-actinin needed to completely arrest thin-filament motility. Force:pCa relations were then determined. Force:pCa data were fit and statistical significance determined as described for the velocity data. For more details, see the online data supplement.

An expanded Materials and Methods section can be found in the online data supplement available at http://www.circresaha.org.

Results

Affinity Chromatography

The aim of these experiments was to assess any large-scale change in affinity between the Tn subunits and whether correct stoichiometry would exist under the conditions of the A-Tm-S1 ATPase and in vitro motility assays, and to test whether C-terminal peptides harbored binding determinants for cTnT or cTnC. The Table summarizes the results obtained from binding of cTnI, cTnI1-192, and the synthetic peptides to the cTnT and cTnC affinity columns. As shown in Figure 1, cTnI and cTnI1-192 did not elute from the cTnT-Sepharose column in the presence of 1 mol/L NaCl, but rather, elution required denaturation with 8 mol/L urea. In fact, cTnI and cTnI1-192 eluted together in a urea gradient; this suggests that the affinity of cTnI1-192 for cTnT is equal or very similar to that of cTnI. The interaction between cTnI and cTnC, in the presence of Ca2+, was sufficiently strong that cTnI failed to elute from the cTnC-Sepharose column in 1 mol/L NaCl or 8 mol/L urea. Elution of either cTnI or cTnI1-192 required the addition of EDTA to chelate the Ca2+ (Table), indicating the Ca2+-sensitive interaction between cTnI and cTnC was not overtly affected by deletion of the C-terminus of cTnI. Furthermore, neither synthetic peptide that comprised the amino acid sequence from the C-terminus of cTnI bound the cTnT- or cTnC-Sepharose affinity columns (Table). Taken together, these data demonstrate that there is no direct interaction between the C-terminus of cTnI and cTnC or cTnT, and that the C-terminal deletion does not grossly disrupt the global interaction between cTnI and the other Tn subunits under these experimental conditions. Nor does deletion of the C-terminus of TnI cause any impediment to the formation of binary cTnI-cTnC complexes or refolded ternary troponin complexes that were used in subsequent functional assays.

View this table:
  • View inline
  • View popup
Table 1.

cTnT and cTnC Affinity Chromatography of cTnI and Its Fragments

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. Affinity chromatography. C-terminus of cTnI does not affect interaction with cTnT. Approximately equimolar amounts of cTnI and cTnI1-192 were applied to a cTnT-Sepharose equilibrated as described in Materials and Methods. The column was washed with equilibration buffer before high-salt buffer was applied. A urea gradient followed the high-salt wash. Fractions (1.5 mL) were analyzed by 12% SDS-PAGE. Gels were stained with Coomassie Blue. The bulk (>90%) of the cTnI and cTnI1-192 remained bound to the column in the presence of 1 mol/L NaCl and could only be eluted under denaturing conditions.

Actin Binding and Effects on A-Tm-S1 ATPase Activity

cTnI and cTnI1-192 displayed equal affinity for actin (F-actin), as assessed by co-sedimentation on ultracentrifugation (Figure 2). The affinity of both cTnI and cTnI1-192 for actin increased in the presence of Tm, consistent with a previous report.16 Under the conditions used in this assay (100 mmol/L NaCl), both cTnI and cTnI1-192 caused actin to form thick bundles (determined by electron microscopy; not shown), when added in excess of F-actin or F-actin-Tm, which precluded proper determination of the maximum binding stoichiometry. TnI-induced aggregation of actin is a complication reported by others,16 but has little impact on the primary observations that the Tm-dependent enhancement of actin binding is preserved in TnI1-192, and that C-terminal truncation does not grossly mitigate binding of cTnI to actin.

Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2. Ultracentrifugation. C-terminus of cTnI does not alter binding to filamentous actin or actin-Tm. Increasing concentrations of cTnI and cTnI1-192 were incubated with F-actin or actin-Tm (5:1 mole ratio) in buffer containing 100 mmol/L NaCl and 5 mmol/L MgCl2 and were ultracentrifuged to pellet both F-actin and any bound protein. Both pellet (P) and supernatant (S, unbound protein) were analyzed. A, Representative Coomassie Blue–stained gels showing protein composition of the supernatants and pellets. B, Gels from panel A, and a duplicate set of gels, were analyzed by densitometry. cTnI (•) and cTnI1-192 (▿) values are shown. Each data point is an average (and range) of the values obtained from the two sets of gels.

It is well documented that binding of cTnI to actin-Tm inhibits A-Tm-S1 ATPase activity by inhibiting binding of myosin S1 to actin.16,25 Figure 3A depicts the concentration-dependent inhibition of A-Tm-S1 ATPase activity by cTnI and cTnI1-192. Both cTnI and cTnI1-192 inhibited the A-Tm-S1 ATPase activity to the same extent at a 1:1 mole ratio of cTnI to actin. At intermediate concentrations, cTnI1-192 was a marginally less effective inhibitor than cTnI, with IC50 values of 0.32 nmol and 0.27 nmol, respectively, and implies reduced affinity of cTnI1-192 for actin-Tm. The reduced affinity was not detected in the ultracentrifugation studies and thus may reveal sensitivity differences between the two types of experiments. Importantly, however, once cTnI1-192 is bound to actin, it inhibits A-Tm-S1 ATPase activity as effectively as full-length cTnI.

Figure3
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 3. Inhibition of A-Tm-S1 ATPase activity by cTnI and cTnI1-192 and its reversal by cTnC. A, A-Tm-S1 ATPase activity was measured as a function of increasing concentration of cTnI (•) or cTnI1-192 (○). B, cTnI (•) and cTnI1-192 (○) were added to actin-Tm such that the mole ratio of cTnI (or cTnI1-192):actin:Tm was 5:1:1. Reversal of this inhibition was determined by increasing the concentrations of cTnC in the presence of Ca2+. A-Tm-S1 ATPase activity is taken to be 100%. Averages and their standard deviations were calculated from triplicate data points. Where error bars are not visible, the standard deviation is small and lies under the symbol.

In the presence of Ca2+, cTnC releases the cTnI- and cTnI1-192-mediated inhibition of the A-Tm-S1 ATPase activity (Figure 3B). Specifically, cTnI or cTnI1-192 was added to actin-Tm in the ratio 5 A/1 Tm/1 TnI (or TnI1-192) in the presence of S1. Addition of cTnC, in the presence of Ca2+, released both cTnI and cTnI1-192 inhibition (Figure 3B); however, the concentration of cTnC required to achieve 50% reversal of A-Tm-S1 ATPase inhibition by cTnI1-192 was less than that required to reverse inhibition by intact cTnI (IC50 values of 0.2 nmol and 0.4 nmol, respectively). It may be interpreted that cTnI1-192 either binds more tightly to Ca2+-cTnC than does full-length cTnI, or that the weakened/altered interaction between cTnI1-192 and actin-Tm (observed in the inhibition studies) enhances the switch of cTnI1-192 to cTnC.

Analysis of Reconstituted cTn

To assess the Ca2+-dependent regulation of ATPase activity, cTn complexes were formed using either cTnI or cTnI1-192, mixed with cTnC and cTnT. Functional Tn complexes composed of either intact cTnI or cTnI1-192 (cTn and cTn1-192, respectively) were prepared and mixed at a 5:1:1 mole ratio of actin:Tm:cTn (or cTn1-192). At low Ca2+, cTn1-192 was not as fully inhibitory as wild-type cTn (45.3±1.9 versus 29.2±0.3 nmol · min−1 · mg−1). At pCa 4.6, cTn1-192 conferred increased maximum ATPase activity, reaching 218±10 nmol · min−1 · mg−1 relative to 142±3 for cTn (Figure 4A), an increase of 54±11%. From the plots normalized for the maximum Ca2+-dependent change in A-Tm-S1 ATPase activity for each troponin (Figure 4A, inset), cTnI1-192 has increased Ca2+ sensitivity compared with intact cTn by approximately 0.1 pCa units. Importantly, under these conditions, cTn1-192 binds to actin-Tm with the same stoichiometry as cTn, when assessed by ultracentrifugation and SDS-PAGE (data not shown).

Figure4
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 4. Ca2+ sensitivity of cTn and cTn1-192. A, Ca2+ dependence of the A-Tm-cTn-S1 activity was determined for reconstituted cTn (•) and cTn1-192 (○). Inset, Results from panel A, normalized with respect to the maximum change in ATPase activity in Ca2+-free and Ca2+-replete conditions, to allow comparison of Ca2+ sensitivity. B, Maximum Ca2+-activated ATPase activity (1 mmol/L CaCl2) was determined for reactions containing mixtures of cTn and cTn1-192. Activity is expressed relative to control A-Tm-Tn-S1 ATPase activity (100%). Averages and their standard deviations were calculated from triplicate data points.

To determine whether cTnI1-192 acts as a “poison peptide” that disproportionately affects the function of regular troponin, as has been observed with FHC mutants of cTnI29 and cTnT,30 Ca2+-activated A-Tm-S1 ATPase activity was determined for various mole fractions of cTn1-192 with respect to Tn (ie, fixed total Tn, Figure 4B). Results are expressed relative to the A-Tm-Tn-S1 ATPase activity (A-Tm-Tn-S1 ATPase=100%). Figure 4B shows that ATPase increased linearly with the increased percentage of cTn1-192. At a cTn1-192:cTn ratio of 0.2, a level of cTn1-192 comparable with levels observed in stunned rat hearts and transgenic mouse hearts that express cTnI1-193 activity was 9.4±3.0% greater than that obtained observed with wild-type cTn alone.

In Vitro Motility and Force Measurements

To determine whether cTnI proteolysis alone is sufficient to cause the decreased force production in previous studies of muscle fibers, we examined both the sliding velocity and in vitro force index of cTn- and cTn1-192-bearing reconstituted thin filaments, using the in vitro motility assay. Figure 5A shows that thin filaments bearing cTn1-192 moved with the same mean unloaded velocity as those bearing cTn (compare 6.2±0.3 versus 6.0±0.3 μm/s, P=NS, respectively). Consistent with results from the A-Tm-S1 ATPase assay, there was an increased Ca2+ sensitization of the velocity-pCa relation when the thin filaments contained cTn1-192 rather than cTn (compare 6.42±0.03 versus 5.99±0.05, respectively. P<0.001).

Figure5
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 5. Measurement of unloaded filament velocity and relative force using the in vitro motility assay. A, Velocity of actin-Tm filaments with bound cTn (•) or bound cTn1-192 (□) was measured as a function of Ca2+. B, Relative isometric force was determined for actin-Tm filaments with bound cTn (▪) or bound cTn1-192 (○) as a function of Ca2+, as described in Materials and Methods.

Thin filaments bearing cTn or cTn1-192 were then compared in a modified in vitro motility assay that provides a reliable proxy for isometric force. In this assay, the load on a thin filament is a function of the relative concentration of the force generator (myosin) and a motion inhibitor (α-actinin) on a nitrocellulose coverslip (see Materials and Methods). The results of these experiments are depicted in Figure 5B. Interaction of these anchored thin filaments, decorated with cTn1-192, with myosin generated only 76±4% (P<0.001) of the force produced by the interaction of myosin with actin-Tm filaments comprised with cTn. The Ca2+ sensitivity of the force-pCa relation was not statistically different between the two types of filaments studied (actin-Tm-cTn–induced pCa50=6.27±0.03, actin-Tm-Tn1-192–induced pCa50=6.25±0.06).

Discussion

This study shows that truncation of cTnI at the C-terminus, to yield cTnI1-192, alters myofilament protein interactions. Specifically, in the A-Tm-S1 ATPase assays, cTnI1-192 was (1) a marginally less effective inhibitor of A-Tm–activated ATPase than TnI, and (2) its inhibitory effects were more effectively antagonized by cTnC in the presence of Ca2+. When cTnI1-192 was incorporated as part of the cTn complex it displayed (3) less effective inhibition of ATPase at low Ca2+, (4) increased Ca2+ sensitivity, and (5) increased maximum A-Tm-S1 ATPase activity compared with cTn at pCa 4.6. (6) This contrasts with both our measurement of a decreased isometric force index, assessed with a modified in vitro motility assay, and previous force measurements of mouse ventricular trabeculae from transgenic mice that express cTnI1-193. Thus, truncation of 17 amino acids from the C-terminus of cTnI causes divergent effects on in vitro ATPase and force and may have implications in vivo. The advantages and limitations of the methods used in this study are outlined in the online data supplement.

Molecular Mechanistic Insights

The data are considered in the context of prominent three-state models of thin-filament regulation. In the biochemical three-state model, advanced by McKillop and Geeves15 and refined by Geeves and Lehrer,33 tropomyosin can exist in equilibrium between three states. In the absence of Ca2+, troponin stabilizes tropomyosin in a state that blocks myosin binding to actin (blocked state). In the presence of Ca2+, the equilibrium shifts and tropomyosin adopts a state that allows myosin to bind strongly to actin (closed state). In the presence of myosin, equilibrium shifts yet again and tropomyosin adopts a state that permits myosin to bind actin, hydrolyze ATP, and cooperatively propagate further binding of myosin to actin (open state). Vibert and colleagues32 have proposed a structural three-state model in which the Ca2+-free troponin constrains tropomyosin in a position on the inner edge of the outer domain of actin that sterically occludes myosin-binding sites (EGTA state). In the presence of Ca2+, troponin allows tropomyosin to move to the outer aspect of the inner domain of actin, which exposes some amino acids on actin that interact strongly with myosin (Ca2+-induced state). Subsequent binding of myosin further nudges tropomyosin onto the inner domain of actin, which exposes all strong myosin-binding determinants on actin (myosin-induced state). The biochemical and structural three-state models are not necessarily equivalent, but provide complementary views of regulation nonetheless. Hereafter, the blocked/EGTA states are designated the B-state, the closed/Ca2+-induced states are designated the C-state, and the open/myosin-induced state is designated M-state.

cTnI, as part of the troponin complex, is posited to act in concert with cTnT27,28 to stabilize/constrain Tm in the B-state. Therefore, the observation that the cTn1-192 does not fully inhibit thin-filament ATPase in the absence of Ca2+ (Figure 4A) could result if (1) the nature of Tn-Tm in the B-state is fundamentally altered, (2) cTnI1-192 alters the B-state–C-state equilibrium transition, or (3) the B-state is in equilibrium with an altered C-state. We believe that (1) is unlikely since cTnI1-192 itself is capable of full ATPase inhibition under saturating conditions (Figure 3A), and preliminary reports of 3D-helical reconstruction from electron micrographs of cTn1-192-bearing filaments show that the B-state position of Tm is unaltered.31 The present study cannot discriminate between (2) and (3), yet the helical reconstruction study, mentioned previously, is consistent with option (3), as it describes an altered C-state in which Tm is shifted azimuthally toward the inner aspect of the inner domain of actin.31

Our observation that cTn1-192 causes Ca2+ sensitization of both the S1 ATPase (Figure 4A) and sliding velocity (Figure 5A) is consistent with previous work by Rarick et al,26 who, by using myofibrils reconstituted with different truncation mutants of cTnI, demonstrated Ca2+ sensitization of myofibrillar ATPase with progressive truncation from the C-terminus. In the context of TnI interactions with its binding partners, the affinity chromatography and ultracentrifugation studies establish that the interactions between cTnI1-192 and cTnT, cTnC, or actin-Tm are not grossly altered when compared with intact cTnI. Rather, it appears that subtle changes have occurred that alter the ability of cTnI1-192 to inhibit the A-Tm-S1 ATPase activity (Figure 3A) and the ability of cTnC to release this inhibition (Figure 3B). The latter experiment suggests that cTnI1-192 might be less effective at maintaining the blocked B-state. Therefore, the Ca2+ sensitization of ATPase and thin-filament sliding velocity may result from a combination of scenarios (2) and (3) above.

Our observation of increased maximum A-Tm-Tn1-192-S1 ATPase activity at pCa 4.6 (Figure 4A) also suggests that the C- to M-state transition is affected by the TnI truncation. Again, the data might be explained by fundamental structural differences in the C- and M-states or a shift of the C- to M-state equilibrium that favors the M-state. As previously stated, preliminary work by Foster et al,31 studying cTn1-192-bearing reconstituted filaments, shows that the C-state position of Tm is “nudged” toward the M-state, which exposes more of the myosin-binding interface on actin. Thus, C-terminal truncation of TnI, through its influence on Tn-Tm may promote binding of myosin to the actin filament. Interestingly, the effect of Tn1-192/Tn ratio (1 mmol/L CaCl2) on ATPase activity was linear (Figure 4B). This suggests that the effect of cTn1-192 is confined locally to a single regulatory unit (7:1:1 mole ratio of actin:Tm:cTn) and is not propagated along the actin filament. Restated, cTnI does not appear to act as a poisoned polypeptide or dominant-negative protein that disproportionately affects the function of the wild-type protein, as has been observed for some Tn mutations that cause familial hypertrophic cardiomyopathy (FHC).29,30

The hypercontractility of filaments regulated by cTn1-192, observed in in vitro ATPase studies, is clearly not reflected under isometric conditions, however. The diminished force index, measured with the modified motility assay, indicates that cTn1-192 causes one of the strongly bound actomyosin intermediates of the crossbridge cycle to be destabilized. The fact that cTn1-192 engenders decreased force production (Figure 5B), yet causes supramaximal ATPase (Figure 4A) and has no effect on maximum thin-filament sliding velocity (Figure 5A), would seem to indicate that the hypocontractility is strain-dependent. The strain-dependent step of the crossbridge cycle, which becomes rate-limiting under isometric conditions, is an isomerism of strongly bound A-M-ADP.35 How might truncation of TnI truncation lead to crossbridge destabilization? Under isometric conditions, actin-bound myosin heads push Tn-controlled Tm to the M-state. It is conceivable that cTn1-192 alters the M-state position of Tm such that thin-filament contacts, with strained and strongly bound myosin, are not fully supported. Ongoing structural studies of cTn1-192-bearing filaments may yet provide an explanation.

Contribution of cTnI Proteolysis in Heart Disease

This study provides an indication of how the proteolysis of cTnI may contribute to the cardiac pathophysiology observed with myocardial stunning and/or pressure overload. First, cTnI1-192 confers decreased maximum force in a defined reconstituted assay (Figure 5B). This confirms that cTnI proteolysis is sufficient to account for the decreased force (steady-state tension) observed in detergent skinned muscle fibers and trabeculae obtained from either rat hearts that have undergone global ischemia5 or from transgenic mouse hearts that express cTnI1-193.8

Second, our observations that cTn1-192 causes divergent effects on ATPase and force in vitro suggest, yet do not prove per se, that proteolysis of cTnI may cause these parameters to be uncoupled in stunned myocardium. It will be important to test this prospect directly, since chemomechanical uncoupling would reduce the efficiency of contraction and have important consequences for the ailing myocardium. Specifically, given that the intracellular concentration of ATP is already reduced during myocardial stunning, inefficient contraction due to poor chemomechanical coupling would further tax low energy reserves. Thus, exertion would lead to increased energy demands within the heart that could not be met.

In conclusion, it is now clear that cTnI modifications occur in diseased human myocardium.11,12 It has become particularly important to determine how C-terminal truncations of cTnI alter crossbridge cycling, since recent studies have shown that cTnI undergoes proteolysis, at its N- and C-termini, in the myocardium of heart-bypass patients.11 Although the fragments in that study may or may not correspond to cTnI1-192 exactly, our present study shows that removal of only 17 amino acids from the C-terminus substantively alters molecular function.

Note Added in Proof

Since submission of this manuscript, the structure of the core domain of Ca2+-saturated cardiac Tn has been determined by X-ray crystallography.34 The C-terminal residues 192 to 209 are not visible in the structure, and the region is believed to be highly flexible.

Acknowledgments

Acknowledgments

D.B.F. was the recipient of an Ontario Graduate Scholarship and an American Heart Association Postdoctoral Fellowship (New England Affiliate). Project funding was provided by the Canadian Institutes of Health Research (J.E.V.E.) and NIH RO1 HL 63038 (A.M. and J.E.V.E.). The authors thank Dr Heather Fraser and Dr Eduardo Marbán for their contribution to this work.

Footnotes

  • This manuscript was sent to Eugene Braunwald, Consulting Editor, for review by expert referees, editorial decision, and final disposition.

  • Jennifer Van Eyk is Chief Scientific Officer of Cardiomics Inc.

  • Original received October 28, 2002; resubmission received July 3, 2003; revised resubmission received September 18, 2003; accepted September 25, 2003.

References

  1. ↵
    Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications, part 1. Circulation. 2001; 104: 2981–2989.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev. 1999; 79: 609–634.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Gao WD, Liu Y, Mellgren R, Marban E. Intrinsic myofilament alterations underlying the decreased contractility of stunned myocardium: a consequence of Ca2+-dependent proteolysis? Circ Res. 1996; 78: 455–465.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Gao WD, Atar D, Backx PH, Marban E. Relationship between intracellular calcium and contractile force in stunned myocardium: direct evidence for decreased myofilament Ca2+ responsiveness and altered diastolic function in intact ventricular muscle. Circ Res. 1995; 76: 1036–1048.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Gao WD, Atar D, Liu Y, Perez NG, Murphy AM, Marban E. Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ Res. 1997; 80: 393–399.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Van Eyk JE, Powers F, Law W, Larue C, Hodges RS, Solaro RJ. Breakdown and release of myofilament proteins during ischemia and ischemia/reperfusion in rat hearts: identification of degradation products and effects on the pCa-force relation. Circ Res. 1998; 82: 261–271.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    McDonough JL, Arrell DK, Van Eyk JE. Troponin I degradation and covalent complex formation accompanies myocardial ischemia/reperfusion injury. Circ Res. 1999; 84: 9–20.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Murphy AM, Kogler H, Georgakopoulos D, McDonough JL, Kass DA, Van Eyk JE, Marban E. Transgenic mouse model of stunned myocardium. Science. 2000; 287: 488–491.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Kogler H, Soergel DG, Murphy AM, Marban E. Maintained contractile reserve in a transgenic mouse model of myocardial stunning. Am J Physiol Heart Circ Physiol. 2001; 280: H2623–H2630.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Feng J, Schaus BJ, Fallavollita JA, Lee TC, Canty JM Jr. Preload induces troponin I degradation independently of myocardial ischemia. Circulation. 2001; 103: 2035–2037.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    McDonough JL, Labugger R, Pickett W, Tse MY, MacKenzie S, Pang SC, Atar D, Ropchan G, Van Eyk JE. Cardiac troponin I is modified in the myocardium of bypass patients. Circulation. 2001; 103: 58–64.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Neagoe C, Kulke M, del Monte F, Gwathmey JK, de Tombe PP, Hajjar RJ, Linke WA. Titin isoform switch in ischemic human heart disease. Circulation. 2002; 106: 1333–1341.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Filatov VL, Katrukha AG, Bulargina TV, Gusev NB. Troponin: structure, properties, and mechanism of functioning. Biochemistry (Mosc). 1999; 64: 969–985.
    OpenUrlPubMed
  14. ↵
    Tobacman LS. Thin filament-mediated regulation of cardiac contraction. Annu Rev Physiol. 1996; 58: 447–481.
    OpenUrlCrossRefPubMed
  15. ↵
    McKillop DF, Geeves MA. Regulation of the interaction between actin and myosin subfragment 1: evidence for three states of the thin filament. Biophys J. 1993; 65: 693–701.
    OpenUrlCrossRefPubMed
  16. ↵
    Geeves MA, Chai M, Lehrer SS. Inhibition of actin-myosin subfragment 1 ATPase activity by troponin I and IC: relationship to the thin filament states of muscle. Biochemistry. 2000; 39: 9345–9350.
    OpenUrlCrossRefPubMed
  17. ↵
    Van Eyk JE, Thomas LT, Tripet B, Wiesner RJ, Pearlstone JR, Farah CS, Reinach FC, Hodges RS. Distinct regions of troponin I regulate Ca2+-dependent activation and Ca2+ sensitivity of the acto-S1-Tm ATPase activity of the thin filament. J Biol Chem. 1997; 272: 10529–10537.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Guo X, Wattanapermpool J, Palmiter KA, Murphy AM, Solaro RJ. Mutagenesis of cardiac troponin I: role of the unique NH2-terminal peptide in myofilament activation. J Biol Chem. 1994; 269: 15210–15216.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Chifflet S, Torriglia A, Chiesa R, Tolosa S. A method for the determination of inorganic phosphate in the presence of labile organic phosphate and high concentrations of protein: application to lens ATPases. Anal Biochem. 1988; 168: 1–4.
    OpenUrlCrossRefPubMed
  20. ↵
    Homsher E, Kim B, Bobkova A, Tobacman LS. Calcium regulation of thin filament movement in an in vitro motility assay. Biophys J. 1996; 70: 1881–1892.
    OpenUrlCrossRefPubMed
  21. ↵
    Homsher E, Wang F, Sellers JR. Factors affecting movement of F-actin filaments propelled by skeletal muscle heavy meromyosin. Am J Physiol. 1992; 262: C714–C723.
    OpenUrlPubMed
  22. ↵
    VanBuren P, Palmiter KA, Warshaw DM. Tropomyosin directly modulates actomyosin mechanical performance at the level of a single actin filament. Proc Natl Acad Sci U S A. 1999; 96: 12488–12493.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    VanBuren P, Alix SL, Gorga JA, Begin KJ, LeWinter MM, Alpert NR. Cardiac troponin T isoforms demonstrate similar effects on mechanical performance in a regulated contractile system. Am J Physiol Heart Circ Physiol. 2002; 282: H1665–H1671.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Bing W, Knott A, Marston SB. A simple method for measuring the relative force exerted by myosin on actin filaments in the in vitro motility assay: evidence that tropomyosin and troponin increased force in a single thin filament. Biochem J. 2000; 350: 693–699.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Syska H, Wilkinson JM, Grand RJ, Perry SV. The relationship between biological activity and primary structure of troponin I from white skeletal muscle of the rabbit. Biochem J. 1976; 153: 375–387.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Rarick HM, Tu XH, Solaro RJ, Martin AF. The C terminus of cardiac troponin I is essential for full inhibitory activity and Ca2+ sensitivity of rat myofibrils. J Biol Chem. 1997; 272: 26887–26892.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Tobacman LS, Nihli M, Butters C, Heller M, Hatch V, Craig R, Lehman W, Homsher E. The troponin tail domain promotes a conformational state of the thin filament that suppresses myosin activity. J Biol Chem. 2002; 277: 27636–27642.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Maytum R, Geeves MA, Lehrer SS. A modulatory role for the troponin T tail domain in thin filament regulation. J Biol Chem. 2002; 277: 29774–29780.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Elliott K, Watkins H, Redwood CS. Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy. J Biol Chem. 2000; 275: 22069–22074.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Redwood C, Lohmann K, Bing W, Esposito GM, Elliott K, Abdulrazzak H, Knott A, Purcell I, Marston S, Watkins H. Investigation of a truncated cardiac troponin T that causes familial hypertrophic cardiomyopathy: Ca2+ regulatory properties of reconstituted thin filaments depend on the ratio of mutant to wild-type protein. Circ Res. 2000; 86: 1146–1152.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Foster DB, Hatch V, Craig RW, Murphy AM, Van Eyk JE, Wang C-LA, Lehman WJ. EM and 3D-image reconstruction of thin filaments reconstituted with cardiac troponin I1-192, a truncation of troponin I associated with myocardial stunning. Biophys J. 2003; 84: 249A. Abstract.
    OpenUrl
  32. ↵
    Vibert P, Craig R, Lehman W. Steric-model for activation of muscle thin filaments. J Mol Biol. 1997; 266: 8–14.
    OpenUrlCrossRefPubMed
  33. ↵
    Geeves MA, Lehrer SS. Dynamics of the muscle thin filament regulatory switch: the size of the cooperative unit. Biophys J. 1994; 67: 273–282.
    OpenUrlCrossRefPubMed
  34. ↵
    Takeda S, Yamashita A, Maeda K, Maeda Y. Structure of the core domain of human cardiac troponin in the Ca2+-saturated form. Nature. 2003; 424: 35–41.
    OpenUrlCrossRefPubMed
  35. ↵
    Gordon AM, Regnier M, Homsher E. Skeletal and cardiac muscle contractile activation: tropomyosin “rocks and rolls.” News Physiol Sci. 2001; 16: 49–55.
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation Research
November 14, 2003, Volume 93, Issue 10
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics

Article Tools

  • Print
  • Citation Tools
    C-Terminal Truncation of Cardiac Troponin I Causes Divergent Effects on ATPase and Force
    D. Brian Foster, Teruo Noguchi, Peter VanBuren, Anne M. Murphy and Jennifer E. Van Eyk
    Circulation Research. 2003;93:917-924, originally published November 13, 2003
    https://doi.org/10.1161/01.RES.0000099889.35340.6F

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation Research.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    C-Terminal Truncation of Cardiac Troponin I Causes Divergent Effects on ATPase and Force
    (Your Name) has sent you a message from Circulation Research
    (Your Name) thought you would like to see the Circulation Research web site.
  • Share on Social Media
    C-Terminal Truncation of Cardiac Troponin I Causes Divergent Effects on ATPase and Force
    D. Brian Foster, Teruo Noguchi, Peter VanBuren, Anne M. Murphy and Jennifer E. Van Eyk
    Circulation Research. 2003;93:917-924, originally published November 13, 2003
    https://doi.org/10.1161/01.RES.0000099889.35340.6F
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Heart Failure and Cardiac Disease
    • Heart Failure
  • Basic, Translational, and Clinical Research
    • Contractile Function

Circulation Research

  • About Circulation Research
  • Editorial Board
  • Instructions for Authors
  • Abstract Supplements
  • AHA Statements and Guidelines
  • Permissions
  • Reprints
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
3355 Keswick Rd
Main Bldg 103
Baltimore, MD 21211
CircRes@circresearch.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured